Skip to main content
2025 PharmSci 360 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Katy Moore, PharmD, RPh

President, Clinical Pharmacology Modeling and Simulation
Allucent
Cary, North Carolina

Moore has >30 yrs in pharmaceutical industry.Joined Allucent, a global CRO, as President, CPMS leading pharmacologists/pharmacometricians/programmers to inform dose/study design/drug development strategies including building customized M&S approaches for benefit:risk evaluation for patients/decisions for drug developers (i.e, Model Informed Drug Development).Moore was Global Head, CPMS at ViiV Healthcare, creating results with different partners/partnerships providing strategy/oversight/application of CPMS/MIDD principles. At VHC, Moore founded/co-chaired Protocol Ph1-2a Review Forum, member on governance/review committees, and founded VHC internship aligned with a career-long commitment to students. Before VHC, Moore joined GSK Worldwide Business Development leading multidisciplinary teams on the S&E of nonclinical/clinical/platform/divestment opportunities for biologics/NCEs/cell therapies.Deals included R&D strategic collaboration/licensing, co-development/marketing, non-profit collaboration/funding, Newco creation/other agreements. Moore had GSK/GW CPMS positions of increasing breadth and responsibility: led Viral Diseases/Oncology groups, member on CPMS LT/Oncology Early Development Unit LT/PRF/Steering Committees.Moore contributed to development, worldwide submissions, and approval of several medicines in adults/children for the treatment/prevention of HIV, other infectious diseases, cancer, and others. Received PharmD from UNC School of Pharmacy, BS degrees in Biological Sciences/Zoology and Pharmacy from CSU and CU, respectively; a Glaxo post-doctoral fellow in PK/PD and joined the industry from the UNC Department of Pharmaceutics. A registered pharmacist, >100 abstracts/manuscripts, and frequent invited speaker.

Disclosure information not submitted.

Presentation(s):